Clinical Trial: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Study Status: Available
Recruit Status: Available
Study Type: Expanded Access: Available for Treatment IND/Protocol
Official Title: An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients With Hemophilia A With Inhibitors
Brief Summary: This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.
Detailed Summary:
Sponsor: Genentech, Inc.
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Genentech, Inc.
Dates:
Date Received: May 12, 2017
Date Started:
Date Completion:
Last Updated: May 12, 2017
Last Verified: May 2017